Is pathologic complete response a good predictor of survival for esophageal adenocarcinoma?
Pathologic complete response (pCR) means no cancer cells are found in the tissue removed during surgery after chemotherapy or chemoradiation given before surgery. For esophageal adenocarcinoma, studies show that patients who achieve pCR tend to live longer than those who do not. However, how well pCR predicts survival depends on the type of treatment and the specific patient group.
What the research says
A large meta-analysis of 26 trials including over 7,400 patients found that overall, pCR was not a good predictor of survival for gastroesophageal adenocarcinoma when all subtypes were combined 3. However, when looking specifically at esophageal adenocarcinoma, pCR was a strong predictor of survival, with a high correlation between treatment effects on pCR and overall survival 3. This suggests that for esophageal adenocarcinoma, pCR is a reliable indicator.
A study using the National Cancer Database of over 16,000 patients with esophageal adenocarcinoma who received trimodal therapy (chemoradiation plus surgery) found that 11.4% achieved pCR, and this rate increased to 17.5% in more recent years (2016-2020) 4. Patients with pCR had a median survival of 86.4 months, which is much longer than those without pCR 4. Another single-institution study of 205 patients reported that 19% achieved pCR, and these patients had significantly better 3-year overall survival (73% vs. 48%) and recurrence-free survival (67% vs. 39%) compared to those with incomplete response 6.
A more recent study of 277 patients treated with the CROSS protocol (a specific chemoradiation regimen) found that 23.8% had a complete response (TRS 0) 5. These patients had longer overall survival compared to those with partial or no response 5. The study also noted that certain factors, like signet ring cell features on biopsy and higher SUV uptake in lymph nodes, were linked to a lower chance of pCR 5.
Interestingly, a meta-analysis focusing on neoadjuvant chemoradiation versus chemotherapy alone for esophageal cancer found that for adenocarcinoma, adding radiation did not significantly increase pCR rates (odds ratio 2.77, p=0.10) 2. This suggests that while pCR is a good predictor of survival, the best way to achieve it may vary by treatment approach.
What to ask your doctor
- What is my chance of achieving a pathologic complete response with the recommended neoadjuvant treatment?
- How does my specific tumor type (adenocarcinoma) and stage affect the likelihood of pCR and survival?
- Are there any factors, like signet ring cells or lymph node activity on PET scan, that might lower my chance of pCR?
- If I achieve pCR, what is the expected long-term survival outlook based on recent studies?
- Should I consider a treatment regimen that has shown higher pCR rates for esophageal adenocarcinoma?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.